Expression and antitumor effects of TRAIL in human cholangiocarcinoma

Hepatology

Volumn 32, Issue 3, 2000, Pages 523-527

  Tanaka, Shinji ^a   Sugimachi, Keishi ^a   Shirabe, Ken ^a   Shimada, Mitsuo ^a   Wands, Jack R ^b   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; TUMOR NECROSIS FACTOR DERIVATIVE;

ADULT; AGED; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL DEATH; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; MALE; NUDE MOUSE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TUMOR GROWTH;

EID: 0033848454     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.9716     Document Type: Article

References (32)

1. A family of ligands for the TNF receptor superfamily
2. Identification and characterization of a new member of the TNF family that induces apoptosis
3. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
4. The receptor for the cytotoxic ligand TRAIL
5. p53 and response to chemotherapy and radiotherapy
6. Mechanisms of hepatic toxicity. I. TNF-induced liver injury
7. Increased plasma tumor necrosis factor in severe alcoholic hepatitis
8. Lethal effect of the anti-Fas antibody in mice
9. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
10. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
11. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
12. A novel receptor for Apo2L/TRAIL contains a truncated death domain
13. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
14. Chemosensitivity in primary liver cancers: Evaluation of the correlation between chemosensitivity and clinicopathological factors
15. Hepatic oncogenesis, IVD. Tumors of the liver
16. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals
17. Establishment and characterization of a cell line from a human cholangiocellular carcinoma
18. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1
19. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium
20. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
21. Safety and antitumor activity of recombinant soluble Apo2 ligand
22. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
23. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype
24. How TRAIL kills cancer cells, but not normal cells
25. The TRAIL to selective tumor death
26. Apoptosis control by death and decoy receptors
27. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
28. Screening the p53 status of human cell lines using a yeast functional assay
29. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
30. TRAIL-R2 A novel apoptosis-mediating receptor for TRAIL
31. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
32. Downregulation of Fas ligand by shedding